within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04C_DrugsUsedInBenignProstaticHypertrophy.G04CA53_TamsulosinAndSolifenacin;
model TamsulosinAndSolifenacin 
   extends Pharmacolibrary.Drugs.ATC.G.G04CA53;

  annotation(Documentation(
    info ="<html><body><p>Tamsulosin and solifenacin is a fixed-dose combination medication used for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men where monotherapy with either agent is not sufficient. Tamsulosin is an alpha 1A-adrenoceptor antagonist improving urine flow, while solifenacin is a muscarinic receptor antagonist that reduces bladder overactivity. This combination is approved and marketed in several countries.</p><h4>Pharmacokinetics</h4><p>There is currently no peer-reviewed publication reporting population pharmacokinetic parameters for the fixed-dose combination of tamsulosin and solifenacin as a single entity. Separate population PK data exist for the individual drugs.</p><h4>References</h4><ol><li><p>van Kerrebroeck, P, et al., &amp; Drake, MJ (2013). Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. <i>European urology</i> 64(6) 1003–1012. DOI:<a href=&quot;https://doi.org/10.1016/j.eururo.2013.07.034&quot;>10.1016/j.eururo.2013.07.034</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23932438/&quot;>https://pubmed.ncbi.nlm.nih.gov/23932438</a></p></li><li><p>Yamada, S, et al., &amp; Tsukada, H (2011). α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics. <i>British journal of clinical pharmacology</i> 72(2) 205–217. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2011.03922.x&quot;>10.1111/j.1365-2125.2011.03922.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21265873/&quot;>https://pubmed.ncbi.nlm.nih.gov/21265873</a></p></li><li><p>Nazir, J, et al., &amp; Ivanescu, C (2015). Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>BMC urology</i> 15 41–None. DOI:<a href=&quot;https://doi.org/10.1186/s12894-015-0031-8&quot;>10.1186/s12894-015-0031-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25956727/&quot;>https://pubmed.ncbi.nlm.nih.gov/25956727</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end TamsulosinAndSolifenacin;
